11 Best Cancer Stocks to Invest In Now

Page 6 of 10

5. Syndax Pharmaceuticals Inc. (NASDAQ:SNDX)

Syndax Pharmaceuticals (NASDAQ:SNDX) is one of the best cancer stocks to invest in now. On February 15, at the Guggenheim biotech conference, Chief Executive Officer Michael Metzger reiterated that Syndax Pharmaceuticals (NASDAQ:SNDX) started 2026 on a strong footing, going by the commercial performance of two key marketed products. In addition, the company is making significant progress on clinical and lifecycle milestones.

The company generated $125 million in annual net sales for Revuforj and $152 million for Niktimvo in the first 11 months. Consequently, the products are showing quarter-over-quarter sales growth. Revuforj’s revenue growth is driven by continued penetration in its labeled indication for KMT2A-rearranged acute myeloid leukemia.

In addition, the company is staring at a tremendous opportunity with Niktimvo in chronic GVHD, targeting 6,500 patients that could expand to about 17,000. Consequently, the company could generate up to $1 billion in third-line plus sales. Syndax has a strategic collaboration with Incyte to co-promote the product.

Syndax Pharmaceuticals (NASDAQ:SNDX) is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative, first-in-class, targeted therapies for cancer, particularly acute leukemia and chronic graft-versus-host disease (cGVHD). They are known for FDA-approved drugs Revuforj (revumenib) and Niktimvo (axatilimab-csfr).

Page 6 of 10